Teva Pharmaceutical Industries (NYSE:TEVA) Raised to “Strong-Buy” at StockNews.com

StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a strong-buy rating in a research note released on Saturday.

A number of other analysts have also recently weighed in on the stock. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an overweight rating in a research note on Thursday, August 1st. UBS Group upped their target price on shares of Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a buy rating in a research note on Wednesday, July 10th. Jefferies Financial Group upped their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a buy rating in a research note on Thursday, June 27th. Piper Sandler reaffirmed an overweight rating and set a $20.00 price objective (up from $19.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, May 13th. Finally, Argus raised shares of Teva Pharmaceutical Industries from a hold rating to a buy rating and set a $20.00 price objective on the stock in a research note on Wednesday, July 10th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $18.67.

Teva Pharmaceutical Industries Trading Down 1.8 %

Teva Pharmaceutical Industries stock opened at $16.69 on Friday. The stock has a market cap of $18.90 billion, a P/E ratio of -39.98, a P/E/G ratio of 1.49 and a beta of 0.90. Teva Pharmaceutical Industries has a 12 month low of $8.06 and a 12 month high of $18.02. The company’s fifty day simple moving average is $16.79 and its 200-day simple moving average is $14.76. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The firm had revenue of $3.82 billion for the quarter, compared to analyst estimates of $3.70 billion. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.35 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now directly owns 45,060 shares of the company’s stock, valued at approximately $777,285. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the sale, the insider now directly owns 45,060 shares in the company, valued at $777,285. The disclosure for this sale can be found here. Insiders have sold a total of 574,256 shares of company stock valued at $9,776,999 in the last ninety days. 0.55% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. Victory Capital Management Inc. lifted its position in shares of Teva Pharmaceutical Industries by 6.0% during the 2nd quarter. Victory Capital Management Inc. now owns 1,906,951 shares of the company’s stock valued at $30,988,000 after acquiring an additional 107,909 shares during the period. Range Financial Group LLC lifted its position in shares of Teva Pharmaceutical Industries by 9.3% during the 2nd quarter. Range Financial Group LLC now owns 61,777 shares of the company’s stock valued at $1,004,000 after acquiring an additional 5,278 shares during the period. TD Asset Management Inc lifted its position in shares of Teva Pharmaceutical Industries by 1.2% during the 2nd quarter. TD Asset Management Inc now owns 225,109 shares of the company’s stock valued at $3,658,000 after acquiring an additional 2,621 shares during the period. CIBC Asset Management Inc lifted its position in shares of Teva Pharmaceutical Industries by 3.4% during the 2nd quarter. CIBC Asset Management Inc now owns 99,750 shares of the company’s stock valued at $1,621,000 after acquiring an additional 3,325 shares during the period. Finally, Natixis Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries by 27.5% during the 2nd quarter. Natixis Advisors LLC now owns 201,352 shares of the company’s stock valued at $3,272,000 after acquiring an additional 43,373 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.